Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2019

View Archived Issues

One and done synthesize and screen IDs aggregation inhibitors

Cerevel initiates phase Ib trial of CVL-231 in schizophrenia

Pilot trial shows efficacy of intratumoral plasmid IL-12 delivery in Merkel cell carcinoma

Ex vivo gene-corrected autologous cell therapy for chronic RDEB wounds: results of phase I/IIa trial

First phase II data for antolimab in eosinophilic gastritis/gastroenteritis presented

Muscarinic M1 receptor antagonist PIPE-359 shows promising in vivo results for the treatment of MS

Second interim OS analysis from phase III study of margetuximab in HER2-positive breast cancer

New variant in CCHCR1 gene found associated with alopecia areata

PhagoMed announces discovery of novel candidate for the treatment of bacterial vaginosis

Second ferroptosis mechanism is tumor cell liability

Biomica, Weizmann Institute of Science to develop treatment for antibiotic-resistant bacteria

Arecor announces a joint research, development and commercialization agreement with JDRF

PTC Therapeutics patents compounds for Huntington's disease

Arvinas presents initial data for its PROTAC targeted protein degraders

Emory University discloses ionotropic glutamate GluN2C/D receptor antagonists

Neuropore Therapies identifies TLR2 antagonists

Agios Pharmaceuticals synthesizes new MAT2A inhibitors

Enanta Pharmaceuticals describes new HBV antivirals

Microbio constructs aptamer targeting LAG-3 for cancer immunotherapy

Rapt Therapeutics studies oral CCR4 antagonist RPT-193 in first-in-human trial

NIH grant supports Vironika's work on small-molecule inhibitors to eradicate HSV latent infection

FDA clears BlueWillow's IND for anthrax vaccine candidate BW-1010

New phase II trial studies suvorexant for comorbid sleep disorder and alcohol dependence

LIDDS reports data from OLE study of Liproca depot in prostate cancer

FDA approves Zejula and companion diagnostic for late-line ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...